ARMCX1 and cancer: Reduced or even undetectable ARMCX1 level is reported within several cancers, like lung cancer (LC), liver cancer, pancreatic cancer, colorectal cancer (CRC), prostate cancer (PCa), and ovarian cancer (OC), and is associated with adverse outcomes [6–8].